Real-world evidence analysis of palbociclib prescribing patterns for patients with advanced/metastatic breast cancer treated in community oncology practice in the USA one year post approval

BACKGROUND: Rapidly evolving understanding of cancer biology has presented novel opportunities to translate that understanding into clinically relevant therapy. Palbociclib, a novel, first-in-class cyclin-dependent kinase (CDK) 4/6 inhibitor was approved in the USA in February 2015 for the treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Kish, J. K., Ward, M. A., Garofalo, D., Ahmed, H. V., McRoy, L., Laney, J., Zanotti, G., Braverman, J., Yu, H., Feinberg, B. A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5932819/
https://www.ncbi.nlm.nih.gov/pubmed/29720233
http://dx.doi.org/10.1186/s13058-018-0958-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5932819/
https://www.ncbi.nlm.nih.gov/pubmed/29720233
http://dx.doi.org/10.1186/s13058-018-0958-2

Ejemplares similares